



**Canadian Blood Services  
Soci t  canadienne du sang**

**PLASMA PRODUCTS AND SERVICES  
BI-WEEKLY PLASMA PRODUCTS UPDATE  
#2012-2  
WEEK OF JANUARY 23, 2012**

---

The following product summaries provide a snapshot of inventories as of the time of writing and highlight some of the existing and evolving inventory issues that may be of interest.

The *Actual Coverage* represents the total inventories held by Canadian Blood Services versus the average Canadian Blood Services weekly demand for the product. The *Target Coverage* represents the desired coverage levels based on risk and supply factors specific to each product. Factors such as availability of product in the global market, licensing issues, manufacturing problems and product recalls/withdrawals all impact on the ability to attain *Target Coverage*.

Manufacturer contact information for reporting adverse events can be found on the last page of this document.

The current version of the Bi-Weekly Plasma Products Update can also be viewed at [www.blood.ca](http://www.blood.ca) under "Plasma Protein Products".

**Albumin 25%**

Actual Coverage: 10.4 weeks  
Target Coverage: 10.0 weeks

**Albumin 5%**

Actual Coverage: 10.9 weeks  
Target Coverage: 10.0 weeks

For the period of April 1, 2011 to March 31, 2012 CSL Behring's Alburex<sup>®</sup> will make up approximately 65% of Canadian Blood Services' supply of Albumin 5%. Alburex<sup>®</sup> 5% is only being delivered to Canadian Blood Services in 500 ml vials and Plasbumin from Talecris in 50 ml and 250 ml vials.

## **IGIV/Subcutaneous Ig**

Actual Coverage: 6.8 weeks  
Target Coverage: 9.5 weeks

Canadian Blood Services issued Customer Letter #2012-02 on January 19, 2012 which provides details on the launch of licensed Hizentra™, 20% Subcutaneous Immune Globulin (Human), supplied by CSL Behring Canada. This letter is available at [www.blood.ca](http://www.blood.ca)

Canadian Blood Services issued Customer Letter #2011-34 on November 21, 2011 to remind customers to familiarize themselves with the information regarding intravenous immunoglobulin associated hemolysis which was provided by the IVIG Hemolysis Pharmacovigilance Group and originally communicated to hospital customers in Customer Letter 2009-02 dated February 19, 2009. This letter is available at [www.blood.ca](http://www.blood.ca)

Canadian Blood Services issued Customer Letter #2011-07 on March 9, 2011 which provides details on the availability of Immune Globulin Products for 2011-2012. This letter is available at [www.blood.ca](http://www.blood.ca). For the 2011-2012 year, CSL Behring's Privigen® and Vivaglobin® are expected to account for 35% of Canadian Blood Services' Ig supply, Baxter's Gammagard products for 14% and Talecris manufactured products for 51%. Canadian Blood Services' staff will be working with customers to bring the distribution ratios in line with the supply over the balance of the fiscal year.

Higher than anticipated demand for calendar year 2011 has seen total IGIV inventory coverage gradually decline to current levels. Inventory is expected to range between six and eight weeks over the balance of the year. This does not include supplier held inventories of approximately six week's coverage.

## **Recombinant FVIII**

Baxter Advate®	Actual Coverage:	11.5 weeks
	Target Coverage:	8.5 weeks
Bayer Kogenate® FS	Actual Coverage:	12.5 weeks
	Target Coverage:	8.5 weeks

Current inventory levels of Advate® and Kogenate® FS are higher than target due to lower than anticipated demand since the beginning of 2011. It is expected that inventory should reach target by the second quarter of fiscal year 2012.

As has been previously communicated, Canadian Blood Services has CSL Behring's Helixate® FS available for distribution in limited quantities. Canadian Blood Services

requests that no additional patients be switched to Helixate® FS.

### **Recombinant FIX (BeneFIX®)**

Pfizer BeneFIX®

Actual Coverage: 11.9 weeks

Target Coverage: 9.5 weeks

### **OTHER**

#### **Plasma Proteins Order Form**

Please use “Factor Concentrates And Unlicensed Plasma Protein Products Order Form”, Version date 2011-08-08 when ordering Factor Concentrates and unlicensed plasma protein products. Otherwise, please use the revised “Volume Expanders/Immune Globulins/Intravenous/Subcutaneous Immune Globulins Order Form”, Version date 2012-01-17 for all other products.

Other products not highlighted in this update are in the 8 – 12 week coverage range. If information is required on products not detailed here please contact:

Keith Buchanan, Manager, Plasma Products – Planning & Supply Management  
Email: Keith.Buchanan@blood.ca

## PLASMA PROTEIN PRODUCTS MANUFACTURER CONTACT INFORMATION FOR REPORTING ADVERSE EVENTS

Please refer to the contact list below when reporting an adverse event to a Plasma Protein Product directly to the manufacturer.

In those jurisdictions with processes that do not include reporting these types of adverse events directly to manufacturers, this information is for reference only.

Supplier	Telephone number	Fax number
Talecris Biotherapeutics	1-866-4TALCAN (1-866-482-5226)	1-866-276-1546
CSL Behring	1-866-773-7721	1-613-232-5031
Baxter BioScience	1-800-387-8399 Ext. 6607	1-855-767-4573
Cangene Corporation	1-800-768-2304	1-800-768-2281 1-204-275-4330
Bayer	1-800-265-7382	1-416-248-9526
Octapharma	1-888-438-0488	1-416-531-8891
Pfizer Canada	1-800-463-6001	1-866-463-6001
Novo Nordisk Canada	1-800-465-4334	1-866-665-2612
Bristol-Myers Squibb	1-866-463-6267	1-888-267-6211
Fresenius Kabi	1-877-953-9002 Ext. 3	1-289-360-6960